Princess Maxima Center For Pediatric Oncology

This study tests a drug called blinatumomab in infants under 1 year old who have a specific, hard-to-treat type of leukemia (KMT2A-rearranged). The goal is to improve how long these babies stay cancer-free and to help them live longer. About 160 infants from around the world will…

This study tests a drug called brigatinib in children and young adults (ages 1 to 25) with certain ALK-positive cancers, including anaplastic large cell lymphoma and inflammatory myofibroblastic tumors. The goal is to find the best dose and see how safe and effective the drug is.…

This study tests a new combination of drugs for children and young adults whose leukemia or lymphoma has returned or not responded to treatment. The drugs include trametinib (a targeted therapy) plus standard chemotherapy. The goal is to find the safest dose and see if the combin…

This trial tests a combination of dasatinib, venetoclax, and chemotherapy in children and young adults with relapsed or refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL). The study has two phases: first to find the safest dose, then to see how well it …

This study tests a combination of two targeted drugs (ruxolitinib and venetoclax) plus standard chemotherapy in children and young adults up to age 21 whose leukemia or lymphoma has returned or not responded to treatment. The goal is to find the safest dose and see how many patie…

This early-phase trial tests a combination of two chemotherapy drugs—Vyxeos (a liposomal form of daunorubicin and cytarabine) and clofarabine—in 25 children and young adults (ages 1-21) with relapsed or refractory acute myeloid leukemia (AML). The main goal is to find the safest …

This study tests a special dye called anti-GD2-800CW that makes neuroblastoma cells glow during surgery. About 22 children with neuroblastoma will receive a single dose of the dye before their operation. The goal is to find the safest and most effective dose to help surgeons see …

This study helps doctors choose the best available therapy for children and young adults with relapsed or hard-to-treat blood cancers. A team of experts reviews each patient's tumor markers and history to recommend a personalized treatment plan. The study does not give any new dr…